Decera Clinical Education Oncology Podcast

Decera Clinical Education
  • 4.9 (10)
  • Courses
  • Updated Semiweekly

Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Decera Clinical Education. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.

  1. 2d ago

    To Treat or Not to Treat: Assessing Risk and Treatment Options in High-Risk SMM

    In this podcast episode, Natalie S. Callander, MD, and Tom Martin, MD, discuss the optimal approaches for the determination of whether a patient with high-risk SMM requires treatment or observation, including: Contemporary Risk Stratification Interpreting Evidence for Early Intervention Treatment vs Observation: Patient Selection Treatment Selection and Sequencing Considerations Safety, Monitoring, and Supportive Care Implementation in Practice Shared Decision-making and Patient Communication Emerging Therapies and Clinical Trials Presenters:  Natalie S. Callander, MD Professor of Medicine Director, Myeloma Clinical and  Cellular Therapy Program University of Wisconsin Carbone  Cancer Center Madison, Wisconsin Tom Martin, MD Professor of Medicine Associate Chief, Hematology/Oncology UCSF Medical Center San Francisco, California Link to full program:https://bit.ly/4wqpYzU Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    To Treat or Not to Treat: Assessing Risk and Treatment Options in High-Risk SMM

  2. 3d ago

    Unmet Needs, Recent Advances, and Expert Insights on Integrating TROP-2 ADCs Into the Care of Patients With TNBC

    Listen in to learn from Thomas Bachelot, MD, PhD, and Mafalda Oliveira, MD, PhD, about recent advances and the integration of anti-TROP2 antibody-drug conjugates (ADCs) into the management of patients with triple-negative breast cancer, including as first-line therapy for those who are not eligible for immunotherapy. Experts will cover: The evolving role of TROP2-directed antibody-drug conjugates (ADCs), including sacituzumab govitecan and datopotamab deruxtecan, in addressing unmet needs in the frontline treatment of TNBC.  Treatment sequencing, reimbursement barriers to recent approvals, and toxicity-informed treatment selection considerations. How to monitor and manage ocular and pulmonary toxicities and care-team readiness for implementing ADC-based therapy in routine practice. Presenters:Thomas Bachelot, MD, PhD Medical Oncology Department of Oncology Léon Bérard Center Lyon, France Mafalda Oliveira, MD, PhD Senior Consultant Medical Oncology Department Vall d’Hebron University Hospital Senior Clinical Investigator Breast Cancer Group Vall d’Hebron Institute of Oncology (VHIO) Vall d’Hebron Barcelona Hospital Campus Barcelona, Spain Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Visit the program page for more content associated with this discussion. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    Unmet Needs, Recent Advances, and Expert Insights on Integrating TROP-2 ADCs Into the Care of Patients With TNBC

  3. Jul 23

    Optimizing Bispecific Antibody Safety and Care Coordination From the Pharmacy in RRMM

    In this episode, Dr Sara Ann Scott and Dr Syeda Saba Kareem discuss toxicities and the safe management of bispecific antibodies used in the treatment of RRMM to improve outcomes for patients, including: The incidence of cytokine release syndrome (CRS), along with the grading system, treatment strategies, and the role of tocilizumab Neurologic toxicities like the clinical manifestation of ICANS and the ICE scoring system used to help assign grading and appropriate treatment with dexamethasone, levetiracetam, and/or high-dose methylprednisolone Infection susceptibilities associated with BCMA-targeted bispecific antibodies and how this varies for GPRC5D-directed targets throughout therapy How to set up and maintain a REMS program Get access to all of our new podcasts by subscribing to the Decera Clinical Education Podcast on Apple Podcasts, YouTube Music, or Spotify. Presenters: Syeda Saba Kareem, PharmD, BCOP Clinical Pharmacy Supervisor Malignant Hematology Moffitt Cancer Center Tampa, Florida Sara A. Scott, PharmD, BCOP Clinical Pharmacy Specialist,  Multiple Myeloma Emory Winship Cancer Institute Atlanta, Georgia Link to full program: https://bit.ly/3RUyrMx Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    Optimizing Bispecific Antibody Safety and Care Coordination From the Pharmacy in RRMM

  4. Jul 22

    Targeting the Future of Pancreatic Cancer Care: RAS, Biomarkers, and Emerging Therapies

    In this episode, Dr Paul E. Oberstein, Dr Andrew H. Ko, and Dr Efrat Dotan discuss recent advances in pancreatic cancer, including: The evolving role of chemotherapy Utility of tumor treating fields for the treatment of locally advanced pancreatic adenocarcinoma Emerging RAS-targeted strategies and novel approaches for CLDN18.2- and MTAP-altered disease The potential impact of these developments on future treatment sequencing and supportive care  Get access to all of our new podcasts by subscribing to the Decera Clinical Education Podcast on Apple Podcasts, YouTube Music, or Spotify. Presenters: Paul E. Oberstein, MD, MS Section Chief, GI Oncology Associate Professor of Medicine Co-Director, KRAS Excellence Initiative Perlmutter Cancer Center NYU Langone Health New York, New York Andrew H. Ko, MD, FASCO Professor of Medicine and Associate Chief Division of Hematology/Oncology University of California San Francisco San Francisco, California Efrat Dotan, MD, MTR Clinical Professor of Medicine (Hematology/Oncology) Executive Medical Director, Penn Medicine, Ann B. Barshinger Cancer Center Penn Center for Cancer Care Innovation, Abramson Cancer Center University of Pennsylvania Philadelphia, Pennsylvania Link to full program: https://bit.ly/44HPR1U Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    Targeting the Future of Pancreatic Cancer Care: RAS, Biomarkers, and Emerging Therapies

  5. Jul 14

    Beyond BCMA: How GPRC5D-Targeted Therapy Fits into Multiple Myeloma Care Today

    Treatment options for patients with multiple myeloma are rapidly evolving. In this podcast episode, Jesus Berdeja, MD, and Amrita Krishnan, MD, FCAP, discuss GPRC5D-directed treatment options for patients with relapsed/refractory multiple myeloma, with a focus on talquetamab, a GPRC5D-directed bispecific antibody. Topic areas covered include: Clinical trial updates and discussion of how findings may translate into clinical practice and FDA approvals Treatment sequencing and patient selection Step-up dosing and what to expect in terms of toxicity management when using a GPRC5D-targeted therapy with on-target, off-tumor effects Presenters: Jesus Berdeja, MD Director of Myeloma Research Greco-Hainsworth Centers for Research  Partner Tennessee Oncology Nashville, Tennessee Amrita Krishnan, MD, FCAP Nason Hollingworth Family Chair in Myeloma Director, Judy and Bernard Briskin Center for Myeloma Professor Hematology/HCT Executive Director of Hematology City of Hope Orange County Irvine, California Content based on an online CME program supported by an educational grant from Johnson & Johnson. Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    Beyond BCMA: How GPRC5D-Targeted Therapy Fits into Multiple Myeloma Care Today

  6. Jul 13

    What Oncology Pharmacists Need to Know About Targeting BCMA in Early Relapsed/Refractory Myeloma

    In this podcast episode, Donald Moore, PharmD, BCPS, BCOP, DPLA, FCCP, FASHP, and Anthony Perissinotti, PharmD, BCOP, discuss the role, efficacy, and safety of agents targeting BCMA in the personalized care of patients with multiple myeloma after disease progression on 1 or 2 previous lines of therapy, including: A Brief Overview of BCMA in Multiple Myeloma Advances in BCMA-Targeted Agents in Progressing Myeloma Selection of BCMA-Directed Therapies for Early Relapse MM Operational Challenges Faced by Oncology Pharmacists Regarding the Incorporation of BCMA-Targeted Agents in Practice Identifying and Managing Adverse Events Associated With BCMA-Directed Agents Presenters:  Donald Moore, PharmD, BCPS, BCOP, DPLA, FCCP, FASHP Clinical Oncology Pharmacy Manager Atrium Health Levine Cancer Institute Charlotte, North Carolina Anthony Perissinotti, PharmD, BCOP Hematology Clinical Pharmacist Specialist University of Michigan Ann Arbor, Michigan Link to full program:https://bit.ly/4gCsgXt Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    What Oncology Pharmacists Need to Know About Targeting BCMA in Early Relapsed/Refractory Myeloma

  7. Jun 30

    Incorporating AKT1 and PIK3CA Pathway Testing and Targeted Therapies in the Management of Advanced Endocrine-Resistant Breast Cancer

    Listen in to learn from Cristina Saura Manich, MD, PhD and Giampaolo Bianchini, MD about practical approaches to PI3K pathway testing, PI3K/AKT-targeted treatment options, and endocrine-based sequencing in metastatic breast cancer. Presenters: Cristina Saura Manich, MD, PhD Head, Breast Cancer Unit Medical Oncology Service Vall d'Hebron University Hospital Breast Cancer Program, Vall d'Hebron Institute of Oncology (VHIO) Barcelona, Spain Giampaolo Bianchini, MD Associate Professor, Universita Vita-Salute San Raffaele Head, Breast Cancer Group, Department of Medical Oncology Head, Clinical Translational and Immunotherapy Research IRCCS Ospedale San Raffaele Milan, Italy Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Visit the program page for more content associated with this discussion.https://bit.ly/4p6W8gP Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    Incorporating AKT1 and PIK3CA Pathway Testing and Targeted Therapies in the Management of Advanced Endocrine-Resistant Breast Cancer

  8. Jun 22

    Personalizing EGFR Mutation–Positive NSCLC Care: Strategies for the Advanced Practice Provider

    Link to claim CME credit: https://bit.ly/4uRr3ir In this episode, Elizabeth Krueger, NP, and Sam Vafadar, DHSc, PA-C, discuss how they optimize first-line EGFR-targeted therapy for patients with EGFR-mutated NSCLC, including: First-line treatment options available for EGFR-mutated NSCLC and the clinical trials that resulted in their approval Adverse event identification and management Generalized strategies to support patient adherence to TKIs Get access to all of our new podcasts by subscribing to the Decera Clinical Education Podcast on Apple Podcasts, YouTube Music, or Spotify Presenters: Elizabeth Krueger, NP Center for Thoracic Cancers Mass General Brigham Cancer Institute Boston, Massachusetts Sam Vafadar, DHSc, PA-C Physician Associate Department of Thoracic Oncology H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    Personalizing EGFR Mutation–Positive NSCLC Care: Strategies for the Advanced Practice Provider
See All (257)

Ratings & Reviews

4.9
out of 5
10 Ratings

About

Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Decera Clinical Education. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.

Information

You Might Also Like